Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway

Cancer Science

Volumn 106, Issue 7, 2015, Pages 857-866

  Liu, Xiao ^a   Wang, Ji Hui ^a   Li, Shun ^a,b   Li, Lin Lin ^a   Huang, Min ^a   Zhang, Yong Hong ^a   Liu, Yang ^a   Yang, Yuan Tao ^a   Ding, Rui ^a   Ke, Yi Quan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

ERK; Glioma; HDAC3; PI3K (AKT); Vasculogenic mimicry

Indexed keywords

GELATINASE A; HISTONE DEACETYLASE 3; LAMININ 5 GAMMA 2; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; LAMC2 PROTEIN, HUMAN; LAMININ;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ADULT; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GLIOMA; HISTONE DEACETYLASES; HUMANS; LAMININ; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84936985204     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12684     Document Type: Article

References (46)

1. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.
2. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012; 18: 2726-32.
3. Wang SY, Ke YQ, Lu GH et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol 2013; 112: 339-45.
4. Zhang LQ, Zhang XD, Xu J et al. Potential therapeutic targets for the primary gallbladder carcinoma: estrogen receptors. Asian Pac J Cancer Prev 2013; 14: 2185-90.
5. Tian F, Zhang X, Tong Y et al. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther 2005; 4: 874-82.
6. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
8. van der Schaft DW, Hillen F, Pauwels P et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005; 65: 11520-8.
9. van der Schaft DW, Seftor RE, Seftor EA et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96: 1473-7.
10. Zhang S, Zhang D, Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007; 254: 157-64.
11. El Hallani S, Boisselier B, Peglion F et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010; 4: 973-82.
12. Hendrix MJ, Seftor EA, Meltzer PS et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001; 98: 8018-23.
13. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006; 5: 228-33.
14. Kim CH, Yoon JS, Sohn HJ et al. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett 2007; 250: 276-83.
15. Sun Q, Zou X, Zhang T, Shen J, Yin Y, Xiang J. The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. Gynecol Oncol 2014; 132: 730-8.
16. Hess AR, Margaryan NV, Seftor EA, Hendrix MJ. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 2007; 236: 3283-96.
17. Wang JY, Sun T, Zhao XL et al. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther 2008; 7 (5): 758-66.
18. Zhang JT, Sun W, Zhang WZ et al. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5gamma2 signaling pathway. BMC Cancer 2014; 14: 193.
19. Seftor RE, Seftor EA, Koshikawa N et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61: 6322-7.
20. Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ. Contribution of the PI3K/MMPs/Ln-5gamma2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol 2013; 42: 2103-15.
21. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-9.
22. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983: 84-100.
23. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
24. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1 (3): 194-202.
25. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci 2013; 124: 651-62.
26. Herranz M, Esteller M. New therapeutic targets in cancer: the epigenetic connection. Clin Transl Oncol 2006; 8: 242-9.
27. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
28. Zhu J, Wan H, Xue C, Jiang T, Qian C, Zhang Y. Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. Brain Res 2013; 1520: 15-22.
29. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004; 6: 744-50.
30. Barter MJ, Pybus L, Litherland GJ et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol 2010; 29: 602-12.
31. Kurundkar D, Srivastava RK, Chaudhary SC et al. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 2013; 266: 233-44.
32. Wang SY, Yu L, Ling GQ et al. Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol Ther 2012; 13 (5): 341-8.
33. Ling G, Wang S, Song Z et al. Transforming growth factor-beta is required for vasculogenic mimicry formation in glioma cell line U251MG. Cancer Biol Ther 2011; 12: 978-88.
34. Yin D, Ong JM, Hu J et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007; 13: 1045-52.
35. Xu J, Sampath D, Lang FF et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 2011; 105: 241-51.
36. Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002; 1: 1173-9.
37. Pecuchet N, Cluzeau T, Thibault C, Mounier N. Vignot S [Histone deacetylase inhibitors: highlight on epigenetic regulation]. Bull Cancer 2010; 97: 917-35.
38. Suzuki K, Oneyama C, Kimura H, Tajima S, Okada M. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway. J Biol Chem 2011; 286: 15698-706.
39. Banik D, Khan AN, Walseng E, Segal BH, Abrams SI. Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. PLoS ONE 2012; 7 (9): e45422.
40. Leoni F, Zaliani A, Bertolini G et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000.
41. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3 (6): 411-21.
42. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 2010; 1806 (1): 18-28.
43. Ma JL, Han SX, Zhu Q et al. Role of Twist in vasculogenic mimicry formation in hypoxic hepatocellular carcinoma cells in vitro. Biochem Biophys Res Commun 2011; 408: 686-91.
44. Zhang S, Li M, Zhang D et al. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patterns formation in melanoma. Lab Invest 2009; 89: 575-86.
45. Wu MZ, Tsai YP, Yang MH et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43 (5): 811-22.
46. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.